Study of the Communication of the Hypothalamus With the Periphery: Impact of Metformin on Leptin Transport in the Cerebrospinal Fluid of Obese Patients. A Monocentric Prospective Study

Who is this study for? Patients with obesity
What treatments are being studied? Metformin
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Obesity, a major health problem, is gradually transforming into a global epidemic. The current obesity treatment with long term efficacy is the bariatric surgery, however, the operative risk of this procedure is high and the post-operative iotrogeny may be important. Obesity is most often associated to the feeding behavior which depends on hypothalamic integration of peripheral signals such as leptin and glucose. High levels of circulating leptin are detected in obese patients. These elevated leptin levels fail to reduce appetite or increase energy expenditure. The mechanism underlying this non-integration of peripheral signals remains to be identified. The ratio of leptin levels in the cereprospinal fluid (CSF) and in the periphery is drastically decreased in obese patients when compared to lean individuals, therefore a defective transport of circulating leptin into the brain via the CSF is maybe linked to obesity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 40
Healthy Volunteers: f
View:

• Adults between 18 and 40 years old

• Body mass index \>30

• For childbearing age women: use of an effective contraceptive method for the duration of the study

• Patients willing to participate in the study and who have signed the informed consent form

• Patients with health insurance

Locations
Other Locations
France
Centre hospitalier d'Arras
RECRUITING
Arras
Contact Information
Primary
Amélie Lansiaux, MD, PhD
lansiaux.amelie@ghcl.net
0033320225741
Backup
Melody Plets, MSc
plets.melody@ghicl.net
0033320225733
Time Frame
Start Date: 2020-07-03
Estimated Completion Date: 2024-09-30
Participants
Target number of participants: 31
Treatments
Experimental: Obese patients
Patients with body mass index \>30
Related Therapeutic Areas
Sponsors
Collaborators: Centre Hospitalier Arras
Leads: Lille Catholic University

This content was sourced from clinicaltrials.gov